Anavex Life Sciences Corp (AVXL)

[orveko_inc]

I don't believe that a patent for Anavex 2-73 which was formerly known as AE37Met is a problem for Anavex

Anavex 2-73 was formerly known as AE37, not AE37Met. AE37Met is the metabolite of AE37 (hence the "Met") and is now known as Anavex 19-144.

Your list contains some applications that are unrelated to A2-73 and A19-144. You also duplicated some and missed others. The following is a list of patents and patent applications that pertain to Anavex 2-73 or to its metabolite, Anavex 19-144:

1) U.S. patent 9,180,106 - "Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity"

Priority date: 02/26/2009
Filing date: 03/12/2014
Grant date: 11/10/2015

Also published as: U.S. application 13/201271, U.S. application 14/205637, WIPO application WO/2010/097641, European application EP/2010/0706348, Chinese application CN/2010/809029, Russian application RU/2011/131708

As it relates to A2-73 or A19-144, this granted U.S. patent covers a method of treating melanoma with A2-73 or A19-144 when combined with either quinacrine, methylene blue, or astemizole.

2) U.S. patent application 13/777471 - "New sigma-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti- cancer, anti-metastatic and anti-(chronic) inflammatory action"

Priority date: 01/17/2007
Filing date: 02/26/2013
Publication date: N/A

Also published as: U.S. application 12/522761, WIPO application WO/2008/087458, European application EP/2008/0702158, Chinese application CN/2008/80002334, Russian application RU/2009/125211

As it relates to A2-73 or A19-144, this patent application, if granted, would cover the preparation of A2-73 and A19-144 as pharmaceutical products for "neuroprotective, anti-amnesic, anticonvulsive, antidepressive, and nooanaleptic-elevating vigilance and anti-fatigue actions"

3) U.S. patent application 13/940352 - "Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection"

Priority date: 03/28/2013
Filing date: 07/12/2013
Publication date: 10/02/2014

Also published as: N/A

This patent application, if granted, would cover a dosage form consisting of A2-73 and either donepezil, galantamine, rivastigmine, or memantine.

4) U.S. patent application 14/395581 - "Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands"

Priority date: 03/28/2013
Filing date: 04/03/2013
Publication date: 03/12/2015

Also published as: WIPO application WO/2014/155138

As it relates to A2-73 or A19-144, this patent application, if granted, would cover a method of treating Alzheimer's with A2-73 or A19-144 when combined with either rivastigmine, galantamine, or donepezil.

5) U.S. patent application 14/865862 - "Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (AE37Met)"

Priority date: 03/28/2013
Filing date: 09/25/2015
Publication: date 01/14/2016

Also published as: N/A

This patent application, if granted, would cover a) the preparation of A19-144 as a pharmaceutical product for the treatment of Alzheimer's, Parkinson's, Huntington's, depression, epilepsy, and brain ischemia, and b) use of A19-144 alongside acetylcholinesterase inhibitors (e.g.: rivastigmine, galantamine, donepezil, etc.).

6) U.S. patent application 15/194792 -

Title and information not yet known, however this patent application is a child of both 14/395581 and 14/865862, so is likely related to Anavex 19-144 and/or Anavex 2-73.

7) PTC patent application PCT/US2015/056172 - "A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy"

Priority date: 10/20/2014
Filing date: 10/19/2015
Publication date: 04/28/2016

Also published as: N/A

This patent application, if granted, would cover a dosage form consisting of A2-73 or A19-144 combined with at least one of the following anti-epileptic drugs: acetazolamide, a benzodiazepines, carbamazepine, chlordiazepoxide, clobazam, a cortiosteroids, eslicarbazepine, eslicarbazepine acetate, ethosuximide, ethotoin, felbamate, lacosamide, lamotrigine, levetiracetam, mephyntoin, mephobarbitol, methsuxamide, oxcarbazepine, paramethadione, perampanel, phenacemide, phenobarbital; phensuxamide; phenytoin, pregabalin, primidone, progabide, rufinamide, stiripentol, sulthiame, tiagabine topiramate, tremethadione, valproate, vigabatrin, zonisamide, donepezil, memantine, galantamine, or rivastigmine.